Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
Holding IPSC?
Track your performance easily
IPSC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.14 - $5.51
Previous Close$1.33
Volume525.94K
Average Volume (3M)363.00K
Market Cap
$106.74M
Enterprise Value-$40.53M
Total Cash (Recent Filing)$198.11M
Total Debt (Recent Filing)$50.84M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 13, 2025EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding84,715,961
10 Day Avg. Volume480,961
30 Day Avg. Volume362,995
Standard Deviation0.28
R-Squared0.06
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.51
Price to Sales (P/S)52.27
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-20.49
Enterprise Value/Gross Profit-18.14
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$7.67Price Target Upside451.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Century Therapeutics News
PremiumCompany Announcements
Century Therapeutics Reports Q3 Results & Strategic Updates
PremiumCompany Announcements
Century Therapeutics Appoints Morgan Conn as New CFO
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ResearchThe overall response rate was 83% for patients treated at the highest dose cohort in the Phase I ELiPSE-1 trial.
Financial PerformanceCentury reported a 2Q24 net loss of $0.38 per share, vs. an estimated net loss of $0.51 per share.
Product DifferentiationCNTY-101 has certain product attributes, such as its NK cell type and passive immune edits, that should contribute to a more commercially attractive, out-patient product profile.
Bears Say
Clinical DataThere is not enough data to confidently suggest that CNTY-101 can replace existing CAR-T therapies for B cell malignancies.
Market CompetitionThe ultra-competitive AID cell therapy space presents significant challenges and a slow pace of clinical execution.
Safety ConcernsThere are fears that safety risks seen in autologous CAR-T therapy for oncology may also be present in treatments for autoimmune diseases.
---
Ownership Overview
3.70% Insiders
5.33% Mutual Funds
0.03% Other Institutional Investors
85.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $1.14 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Currently, no data Available
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 126 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.451 by $0.081.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -$0.43.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 84,715,960 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.451. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Century Therapeutics?
Among the largest hedge funds holding Century Therapeutics’s share is Baker Bros Advisors LP. It holds Century Therapeutics’s shares valued at 2M.
---
Century Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (451.80% Upside)
$7.67 (451.80% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 66%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $17.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.43%
12-Months-Change
Fundamentals
Return on Equity
-62.61%
Trailing 12-Months
Asset Growth
-2.25%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Month Forecast
Average Price Target
$7.67
▲(451.80% Upside)
Technical Analysis
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-39.76%
reiterated a buy rating yesterday
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -39.76% per trade.
---